![Janssen Announces U.S. FDA Approval of Novel TREMFYA® (guselkumab) One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis Janssen Announces U.S. FDA Approval of Novel TREMFYA® (guselkumab) One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis](https://mma.prnewswire.com/media/827366/Janssen_TREMFYA_Product_Packaging.jpg?p=facebook)
Janssen Announces U.S. FDA Approval of Novel TREMFYA® (guselkumab) One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TREMFYA safely and effec
![Janssen Announces U.S. FDA Approval of Novel TREMFYA® (guselkumab) One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis Janssen Announces U.S. FDA Approval of Novel TREMFYA® (guselkumab) One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis](https://mma.prnewswire.com/media/827365/Janssen_TREMFYA_One_Press_Injector.jpg?p=facebook)
Janssen Announces U.S. FDA Approval of Novel TREMFYA® (guselkumab) One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis
![IL-23 inhibitors stage fierce competition in psoriasis, arthritis treatment market < Pharma < Article - KBR IL-23 inhibitors stage fierce competition in psoriasis, arthritis treatment market < Pharma < Article - KBR](https://cdn.koreabiomed.com/news/photo/202304/20816_20971_06.jpg)